Novartis: FDA approval for wet AMD drug
(CercleFinance.com) - Novartis announced on Tuesday that the US FDA has approved the Beovu (brolucizumab) injection for the treatment of the wet form of age-related macular degeneration (AMD).
The approval is based on data from the Hawk and Harrier Phase III clinical trials, in which Beovu demonstrated non-inferiority to aflibercept in the mean change in visual acuity corrected at best after one year of treatment.
"Estimates suggest that in 2020, 1.75 million people in the U.S. will be living with wet AMD, making it a growing public health concern," Novartis said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The approval is based on data from the Hawk and Harrier Phase III clinical trials, in which Beovu demonstrated non-inferiority to aflibercept in the mean change in visual acuity corrected at best after one year of treatment.
"Estimates suggest that in 2020, 1.75 million people in the U.S. will be living with wet AMD, making it a growing public health concern," Novartis said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.